Once daily dolutegravir superior to darunavir/ritonavir in 96-week follow up

postato in: Senza categoria | 0

Treatment with a triple
antiretroviral combination containing once-daily integrase inhibitor dolutegravir
(Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir
(Prezista) over 96 weeks of follow up,Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported at the Internatinal Congress of
Drug Therapy in HIV Infection in Glasgow last week.

Dolutegravir is also a component of

Once daily dolutegravir superior to darunavir/ritonavir in 96-week follow up

postato in: Senza categoria | 0

Treatment with a triple
antiretroviral combination containing once-daily integrase inhibitor dolutegravir
(Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir
(Prezista) over 96 weeks of follow up,Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported at the Internatinal Congress of
Drug Therapy in HIV Infection in Glasgow last week.

Dolutegravir is also a component of

Sofosbuvir/ledipasvir cures nearly all genotype 1 HIV/HCV coinfected patients

postato in: Senza categoria | 0

All but one
participant treated with a co-formulation of sofosbuvir and ledipasvir (Harvoni) achieved sustained virological
response at 12 weeks post-treatment in a study looking at traditionally hard-to-treat
HIV/HCV coinfected patients, researchers reported Sunday at the American Association for the Study
of Liver Diseases (AASLD) Liver Meeting in Boston.
Sofosbuvir/ledipasvir –
a combination nucleotide HCV polymerase

Sustained virological response to hepatitis C treatment reduces mortality, liver cancer and liver transplants

postato in: Senza categoria | 0

People who achieve
sustained virological response (SVR) when treated with interferon-based therapy
for hepatitis C have a lower risk of death, are less likely to develop liver
cancer and need fewer liver transplants than those who were treated but not cured,
according to results from a meta-analysis of more than 34,000 patients
presented Sunday at

Protease inhibitor monotherapy: darunavir/ritonavir less effective than three-drug therapy

postato in: Senza categoria | 0

Darunavir/ritonavir monotherapy results in a lower rate of
viral suppression after 48 weeks when compared to darunavir/ritonavir plus two
nucleoside analogues, but may be just as effective as three-drug therapy in
people with nadir CD4 cell counts above 200, according to a 48-week analysis of
the PROTEA study presented on Thursday at the International

Truvada PrEP use rising in United States, especially among men

postato in: Senza categoria | 0

The number of people
using Truvada for pre-exposure
prophylaxis (PrEP) in the US is increasing and a growing proportion of users
are men, according to an analysis of data from approximately half of American
pharmacies presented this week at the HIV Drug Therapy Glasgow conference.
PrEP refers to the use of
antiretroviral medications to prevent HIV

Truvada PrEP use rising in United States, especially among men

postato in: Senza categoria | 0

The number of people
using Truvada for pre-exposure
prophylaxis (PrEP) in the US is increasing and a growing proportion of users
are men, according to an analysis of data from approximately half of American
pharmacies presented this week at the HIV Drug Therapy Glasgow conference.
PrEP refers to the use of
antiretroviral medications to prevent HIV

Truvada PrEP use rising in United States, especially among men

postato in: Senza categoria | 0

The number of people
using Truvada for pre-exposure
prophylaxis (PrEP) in the US is increasing and a growing proportion of users
are men, according to an analysis of data from approximately half of American
pharmacies presented this week at the HIV Drug Therapy Glasgow conference.
PrEP refers to the use of
antiretroviral medications to prevent HIV

Il virus immaturo fotografato per la prima volta in HD

postato in: Senza categoria | 0

Il virus Hiv ancora ‘bambino’, immaturo e incapace di infettare, è stato fotografato per la prima volta in alta definizione dai ricercatori del Laboratorio europeo di biologia molecolare (Embl) in collaborazione con l’università tedesca di Heidelberg. Le immagini, pubblicate su Nature, dimostrano che i ‘mattoni’ che compongono il virus sono disposti in una maniera del tutto inattesa: conoscere la loro esatta posizione permetterà di sviluppare nuovi farmaci mirati per bloccare il processo di maturazione.

One third of TB cases in Eastern European HIV clinic survey multi-drug resistant

postato in: Senza categoria | 0

Around one-third of people
living with HIV in Eastern Europe who were diagnosed with TB had multi-drug
resistant TB, according to the findings of a global study of TB/HIV management
in high- and middle-income countries. The findings of the study, conducted by EuroCoord, were presented by Anne Marie Efsen of the University of

1 9 10 11 12 13 14 15